CymaBay Therapeutics (NASDAQ: CBAY)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.320 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of CymaBay Therapeutics (NASDAQ: CBAY) through any online brokerage.
Other companies in CymaBay Therapeutics’s space includes: Aerie Pharmaceuticals (NASDAQ:AERI), WAVE Life Sciences (NASDAQ:WVE), Verona Pharma (NASDAQ:VRNA), Provention Bio (NASDAQ:PRVB) and Rani Therapeutics Hldgs (NASDAQ:RANI).
The latest price target for CymaBay Therapeutics (NASDAQ: CBAY) was reported by B. Riley Securities on Wednesday, May 18, 2022. The analyst firm set a price target for 8.00 expecting CBAY to rise to within 12 months (a possible 188.81% upside). 4 analyst firms have reported ratings in the last year.
The stock price for CymaBay Therapeutics (NASDAQ: CBAY) is $2.77 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for CymaBay Therapeutics.
CymaBay Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for CymaBay Therapeutics.
CymaBay Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.